Bioluminescent Orthotopic Syngeneics for I/O Assessment

There are limited treatment options available for hepatocellular carcinoma (HCC), which is an aggressive cancer type. Checkpoint inhibitors could be a valid new therapeutic option, which require suitable, immunocompetent models for preclinical evaluation.